echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Liglitin has been shown to have cardiovascular and kidney safety in adults with type 2 diabetes in Asia.

    Liglitin has been shown to have cardiovascular and kidney safety in adults with type 2 diabetes in Asia.

    • Last Update: 2020-09-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    · In addition, an Asian population subgroup analysis of carmelina® cardiovascular outcome trials showed that in adults with type 2 diabetes in Asia with a higher risk of cardioneedle, Liglitatin had similar cardiovascular and kidney safety characteristics compared to placebo Bronger Ingham published the results of the Asian subgroup analysis of the CAROLINA® cardiovascular outcome trial, focusing on asian adults with type 2 diabetes with increased cardiovascular risk.
    the results, published in Diabetology International, showed that Liglitatin did not increase cardiovascular risk in the Asian population compared to Gremerin, and was consistent with the results of the entire CAROLINA® study population.
    , the prevalence of type 2 diabetes in Asia has increased rapidly.
    32019, the International Diabetes Federation estimates that more than half (251 million) of the world's 463 million people with diabetes are in Southeast Asia and the Western Pacific.
    4 pre-set CAROLINA® subgroup analysis included 933 Asian adult patients, accounting for 15.5 percent of the 6,033 subjects in the CAROLINA® study.
    Asian subjects in the CAROLINA ® study, liglitatin had a lower risk of hypoglycemia and a lower risk of weight gain than gremetin therapy.
    13.1 per cent of Asian patients treated with liglitatin had any severe hypoglycemia, while 42.1 per cent of Asian patients treated with glitatin.
    weight loss in the ligliglitin treatment group, with an average difference of -1.82 kg compared to Gremethal.
    CAROLINA ® and CARMELINA® are two cardiovascular outcome trials of Liglitin that provide the most comprehensive data set of long-term safety of DPP-4-inhibitors.
    A subgroup analysis of the CARMELINA® trial, published in The International Journal of Diabetology in October 2019, showed that liglitatin did not increase the risk of cardiovascular or kidney events in adults with type 2 diabetes in Asia who were at high risk of heart and/or kidney disease compared to placebos.
    these results are consistent with those of ® carmelina study population as a whole.
    these trials demonstrate the cardiovascular and kidney safety characteristics of liglitatin in a wide range of adults with type 2 diabetes in Asia.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.